{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T17:19:31.368135+00:00","company":{"ticker":"VTAK","cik":1716621,"company_name":"Catheter Precision, Inc."},"pagination":{"limit":100,"returned":78,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Anaya Holdings LLC","detail":"lease","count":1,"first_seen":"2022-11-03T23:59:59+00:00","last_seen":"2022-11-03T23:59:59+00:00","evidence_fact_ids":[200019]},{"display_name":"Catheter Precision, Inc., Rapid Merger Sub 1, Inc., and Rapid Merger Sub 2, LLC","detail":"merger","count":1,"first_seen":"2023-01-13T23:59:59+00:00","last_seen":"2023-01-13T23:59:59+00:00","evidence_fact_ids":[186146]},{"display_name":"David A. Jenkins and FatBoy Capital, LP","detail":"equity_purchase","count":1,"first_seen":"2026-02-12T23:59:59+00:00","last_seen":"2026-02-12T23:59:59+00:00","evidence_fact_ids":[32594]},{"display_name":"Ladenburg Thalmann & Co. Inc.","detail":"atm_program","count":1,"first_seen":"2025-11-21T23:59:59+00:00","last_seen":"2025-11-21T23:59:59+00:00","evidence_fact_ids":[156600]},{"display_name":"Volato Group, Inc.","detail":"equity_purchase","count":1,"first_seen":"2026-06-08T10:16:04+00:00","last_seen":"2026-06-08T10:16:04+00:00","evidence_fact_ids":[97265]}],"lender":[{"display_name":"Cardionomic, LLC","detail":"loan","count":2,"first_seen":"2025-04-23T23:59:59+00:00","last_seen":"2025-05-08T23:59:59+00:00","evidence_fact_ids":[95359,102824]}],"ma_counterparty":[{"display_name":"Catheter Precision, Inc.","detail":"acquisition","count":2,"first_seen":"2023-01-13T23:59:59+00:00","last_seen":"2023-01-19T23:59:59+00:00","evidence_fact_ids":[185507,186148]},{"display_name":"Cardionomic, LLC","detail":"acquisition","count":1,"first_seen":"2025-05-08T23:59:59+00:00","last_seen":"2025-05-08T23:59:59+00:00","evidence_fact_ids":[83262]}]},"facts":[{"fact_type":"material_agreement","fact_key":"f8bef3fe49d3089c11b9be957405fa19d8e4f0a8","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-06-08T10:16:04+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Volato Group, Inc.","effective_date":"2026-06-07","item_codes_triggered":["1.01"],"value_text":"$1,000,000"},"claim":"Catheter Precision, Inc. entered into Securities Purchase Agreement with Volato Group, Inc. valued at $1,000,000 (effective 2026-06-07).","evidence_excerpt":"On June 7, 2026, Catheter Precision, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) between Volato Group, Inc. (NYSE American: SOAR), a Delaware corporation (“Volato”), the Company, and other investors party thereto, pursuant to which the Company agreed to purchase 2,941,176 shares of common stock, par value $0.0001 per share, of Volato (“Shares”) at a per share purchase price of $0.34 per share, for an aggregate purchase price of $1,000,000 (the “Subscription Amount”), in a private placement transaction (the “Private Placement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-019779","anchor_url":"https://secwatch.observer/filing/0001437749-26-019779#claim-f8bef3fe49d3089c11b9be957405fa19d8e4f0a8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926019779/0001437749-26-019779-index.htm"},{"fact_type":"earnings_release","fact_key":"82008bf54da2ca8ed2709b38dc7ceaf3ae0ff72d","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-05-18T20:17:11+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter of 2026","report_date":"2026-05-18","result_type":"reported_results","revenue_text":null},"claim":"Catheter Precision, Inc. reported financial results for first quarter of 2026.","evidence_excerpt":"On May 18, 2026, Catheter Precision, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-26-017612","anchor_url":"https://secwatch.observer/filing/0001437749-26-017612#claim-82008bf54da2ca8ed2709b38dc7ceaf3ae0ff72d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926017612/0001437749-26-017612-index.htm"},{"fact_type":"equity_issuance","fact_key":"9ea315522954c6456a58b0ee46840d41bd239ecd","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-04-23T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"aggregate gross proceeds of $3,470,000","effective_date":"2026-04-21","item_codes_triggered":["3.02"],"purchaser":"the purchasers signatory thereto","security_type":"preferred_stock","shares_text":"3,470 shares"},"claim":"Catheter Precision, Inc. issued 3,470 shares of preferred stock to the purchasers signatory thereto for aggregate gross proceeds of $3,470,000.","evidence_excerpt":"Issuance of Series C-2 Convertible Preferred Stock On April 21, 2026, Catheter Precision, Inc. (the \"Company\") consummated the closing (the \"Series C-2 Closing\") of its previously disclosed sale and issuance of an aggregate of 3,470 shares of the Company's newly designated Series C-2 Convertible Preferred Stock, par value $0.0001 per share and stated value of $1,000 per share (the \"Series C-2 Preferred Stock\"), for aggregate gross proceeds of $3,470,000.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-013183","anchor_url":"https://secwatch.observer/filing/0001437749-26-013183#claim-9ea315522954c6456a58b0ee46840d41bd239ecd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926013183/0001437749-26-013183-index.htm"},{"fact_type":"governance_change","fact_key":"48394f657b0ba5d107a0abf93c93607ced792365","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-04-23T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-04-17","item_codes_triggered":["5.03"],"summary_text":"Filed Series C-2 Certificate of Designation designating 3,470 shares as Series C-2 Convertible Preferred Stock and Series D Certificate of Designation designating 11,028 shares as Series D Convertible Preferred Stock"},"claim":"Catheter Precision, Inc.: Filed Series C-2 Certificate of Designation designating 3,470 shares as Series C-2 Convertible Preferred Stock and Series D Certificate of Designation designating 11,028 shares as Series D Convertible Preferred Stock (effective 2026-04-17).","evidence_excerpt":"On April 17, 2026, the Company filed each of the Series C-2 Certificate of Designation and the Series D Certificate of Designation with the Secretary of State of the State of Delaware.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-013183","anchor_url":"https://secwatch.observer/filing/0001437749-26-013183#claim-48394f657b0ba5d107a0abf93c93607ced792365","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926013183/0001437749-26-013183-index.htm"},{"fact_type":"earnings_release","fact_key":"e8801e18444e728778774ca99bf724cdd909130a","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-03-31T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$17.2 million","period_text":"the quarter and year ended December 31, 2025","report_date":"2026-03-31","result_type":"reported_results","revenue_text":"$819 thousand"},"claim":"Catheter Precision, Inc. reported the quarter and year ended December 31, 2025 results: revenue $819 thousand, net income $17.2 million.","evidence_excerpt":"create a compelling framework for accelerated growth and a potential re-rating as execution milestones are achieved. 2025 Full Year Financial Highlights ● 2025 Revenue of $819 thousand, a 95% increase over 2024 Revenue of $420 thousand. ● 2025 Gross Margin of 92.3% compared with 90.0% in 2024. ● Net Loss of $17.2 million of which $7.8 million was non-cash","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-26-010721","anchor_url":"https://secwatch.observer/filing/0001437749-26-010721#claim-e8801e18444e728778774ca99bf724cdd909130a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926010721/0001437749-26-010721-index.htm"},{"fact_type":"equity_issuance","fact_key":"0db228ff7f6aefb7179405a44b66ead68e260571","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-03-09T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"aggregate purchase price of $1,853,000.00","effective_date":"2026-03-09","item_codes_triggered":["3.02","3.03"],"purchaser":"accredited investors","security_type":"preferred_stock","shares_text":"1,853 shares of Series C-3 Convertible Preferred Stock"},"claim":"Catheter Precision, Inc. issued 1,853 shares of Series C-3 Convertible Preferred Stock of preferred stock to accredited investors for aggregate purchase price of $1,853,000.00.","evidence_excerpt":"pursuant to the Financing Purchase Agreement, the Purchasers agreed to purchase (i) 1,853 shares of the Company’s newly-designated Series C-2 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, for an aggregate purchase price of $1,853,000.00 (the “Series C-2 Preferred Stock”), and (ii) 1,853 shares of the Company’s newly-designated Series C-3 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, for an aggregate purchase price of $1,853,000.00 (the “Series C-3 Preferred Stock” and, together with the Series C-1 Preferred Stock and Series C-2 Preferred Stock, the “Initial Preferred Stock”)","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001437749-26-007380","anchor_url":"https://secwatch.observer/filing/0001437749-26-007380#claim-0db228ff7f6aefb7179405a44b66ead68e260571","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926007380/0001437749-26-007380-index.htm"},{"fact_type":"equity_issuance","fact_key":"4ca7bfe5ba4dded7f1e7bf8f3979e79348c723a9","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-03-09T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"aggregate purchase price of $1,853,000.00","effective_date":"2026-03-09","item_codes_triggered":["3.02","3.03"],"purchaser":"accredited investors","security_type":"preferred_stock","shares_text":"1,853 shares of Series C-2 Convertible Preferred Stock"},"claim":"Catheter Precision, Inc. issued 1,853 shares of Series C-2 Convertible Preferred Stock of preferred stock to accredited investors for aggregate purchase price of $1,853,000.00.","evidence_excerpt":"pursuant to the Financing Purchase Agreement, the Purchasers agreed to purchase (i) 1,853 shares of the Company’s newly-designated Series C-2 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, for an aggregate purchase price of $1,853,000.00 (the “Series C-2 Preferred Stock”), and (ii) 1,853 shares of the Company’s newly-designated Series C-3 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, for an aggregate purchase price of $1,853,000.00 (the “Series C-3 Preferred Stock” and, together with the Series C-1 Preferred Stock and Series C-2 Preferred Stock, the “Initial Preferred Stock”)","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001437749-26-007380","anchor_url":"https://secwatch.observer/filing/0001437749-26-007380#claim-4ca7bfe5ba4dded7f1e7bf8f3979e79348c723a9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926007380/0001437749-26-007380-index.htm"},{"fact_type":"equity_issuance","fact_key":"d97714760b20ba8931f611d14d15a95ffeba4c57","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-03-09T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"aggregate purchase price of $1,853,000","effective_date":"2026-03-09","item_codes_triggered":["3.02","3.03"],"purchaser":"accredited investors","security_type":"preferred_stock","shares_text":"1,853 shares of Series C-1 Convertible Preferred Stock"},"claim":"Catheter Precision, Inc. issued 1,853 shares of Series C-1 Convertible Preferred Stock of preferred stock to accredited investors for aggregate purchase price of $1,853,000.","evidence_excerpt":"On March 9, 2026, Catheter Precision, Inc. (the “Company”) entered into a securities purchase agreement (the “Financing Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement Financing”) of an aggregate of 1,853 shares of the Company’s Series C-1 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, initially convertible into up to 1,295,805  shares of common stock, par value $0.0001 per share (“Common Stock”), at an initial conversion price of $1.43 per share (the “Series C-1 Preferred Stock”) for an aggregate purchase price of $1,853,000","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-26-007380","anchor_url":"https://secwatch.observer/filing/0001437749-26-007380#claim-d97714760b20ba8931f611d14d15a95ffeba4c57","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926007380/0001437749-26-007380-index.htm"},{"fact_type":"governance_change","fact_key":"a6053ab3715b9606a5917fd642ab98f77061f848","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-03-09T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-03-06","item_codes_triggered":["5.03"],"summary_text":"Amendment to Series C-1 Certificate of Designations to increase authorized shares from 1,783.33 to 3,636.33"},"claim":"Catheter Precision, Inc.: Amendment to Series C-1 Certificate of Designations to increase authorized shares from 1,783.33 to 3,636.33 (effective 2026-03-06).","evidence_excerpt":"In connection with the entrance into the Financing Purchase Agreement, the holders of the majority of the outstanding shares of Series C-1 Preferred Stock agreed to amend the Series C-1 Certificate of Designations by filing a Certificate of Amendment (“Certificate of Amendment”) to the Series C-1 Certificate of Designations with the Secretary of State of the State of Delaware (the “Secretary of State”) to increase the number of authorized shares of Series C-1 Preferred Stock from 1,783.33 to 3,636.33, in order to authorize a sufficient number of shares of Preferred Stock for the transactions contemplated by the Acquisition Purchase Agreement. On March 6, 2026, the Company filed the Certificate of Amendment with the Secretary of State, thereby amending the Certificate of Designations.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-007380","anchor_url":"https://secwatch.observer/filing/0001437749-26-007380#claim-a6053ab3715b9606a5917fd642ab98f77061f848","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926007380/0001437749-26-007380-index.htm"},{"fact_type":"material_agreement","fact_key":"1b05553c7e4837cd1e36141edaa208a6a5f99557","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-03-09T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Financing Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain accredited investors","effective_date":"2026-03-09","item_codes_triggered":["1.01"],"value_text":"an aggregate purchase price of $1,853,000"},"claim":"Catheter Precision, Inc. entered into Financing Purchase Agreement with certain accredited investors valued at an aggregate purchase price of $1,853,000 (effective 2026-03-09).","evidence_excerpt":"On March 9, 2026, Catheter Precision, Inc. (the “Company”) entered into a securities purchase agreement (the “Financing Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-007380","anchor_url":"https://secwatch.observer/filing/0001437749-26-007380#claim-1b05553c7e4837cd1e36141edaa208a6a5f99557","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926007380/0001437749-26-007380-index.htm"},{"fact_type":"equity_issuance","fact_key":"b8ed63db6d40c2ca204e6347b4a9502104fa0180","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-02-12T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"accrued royalty amounts totaling a net present value equal to $9,489,487.81","effective_date":"2026-02-12","item_codes_triggered":["3.02"],"purchaser":"David A. Jenkins and FatBoy Capital, LP","security_type":"preferred_stock","shares_text":"9,489.488 shares of Series J Preferred Stock"},"claim":"Catheter Precision, Inc. issued 9,489.488 shares of Series J Preferred Stock of preferred stock to David A. Jenkins and FatBoy Capital, LP for accrued royalty amounts totaling a net present value equal to $9,489,487.81.","evidence_excerpt":"Settlement Agreements dated January 9, 2023 between the Company and the Holders previously disclosed by the Company accrued royalty amounts totaling a net present value equal to $9,489,487.81 as of December 31, 2025 are being exchanged for 9,489.488 shares of Series J Preferred Stock, collectively.  Per the Exchange Agreements, the accrued royalty amounts and the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-003940","anchor_url":"https://secwatch.observer/filing/0001437749-26-003940#claim-b8ed63db6d40c2ca204e6347b4a9502104fa0180","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926003940/0001437749-26-003940-index.htm"},{"fact_type":"governance_change","fact_key":"061fcd77f48b1602c2657a0f2d301537a4ba00b7","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-02-12T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-02-09","item_codes_triggered":["5.03"],"summary_text":"Filed Series J Certificate of Designation with Delaware Secretary of State on February 9, 2026, as corrected on February 12, 2026, to establish Series J Convertible Preferred Stock."},"claim":"Catheter Precision, Inc.: Filed Series J Certificate of Designation with Delaware Secretary of State on February 9, 2026, as corrected on February 12, 2026, to establish Series J Convertible Preferred Stock (effective 2026-02-09).","evidence_excerpt":"as further described by the Certificate of Designation of Preferences, Rights and Limitations of Series J Convertible Preferred Stock which was filed with the Delaware Secretary of State on February 9, 2026, as corrected on February 12, 2026 (the \"Series J Certificate of Designation\")","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-26-003940","anchor_url":"https://secwatch.observer/filing/0001437749-26-003940#claim-061fcd77f48b1602c2657a0f2d301537a4ba00b7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926003940/0001437749-26-003940-index.htm"},{"fact_type":"material_agreement","fact_key":"6a0f30723c1caf2669901a01c6a6c62c0e62968e","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-02-12T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Series J Exchange Agreements","agreement_type":"equity_purchase","counterparty":"David A. Jenkins and FatBoy Capital, LP","effective_date":"2026-02-12","item_codes_triggered":["1.01"],"value_text":"$9,489,487.81"},"claim":"Catheter Precision, Inc. entered into Series J Exchange Agreements with David A. Jenkins and FatBoy Capital, LP valued at $9,489,487.81 (effective 2026-02-12).","evidence_excerpt":"On February 12, 2026, Catheter Precision, Inc., a Delaware corporation (the \"Company\"), entered into Series J Exchange Agreements (the \"Exchange Agreements\") with David A. Jenkins and FatBoy Capital, LP. (the \"Holders\") to convert royalty rights and accrued royalty right amounts into 2,491.293 shares and 6,998.195 shares, respectively of the Company's newly created Series J Convertible Preferred Stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-003940","anchor_url":"https://secwatch.observer/filing/0001437749-26-003940#claim-6a0f30723c1caf2669901a01c6a6c62c0e62968e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926003940/0001437749-26-003940-index.htm"},{"fact_type":"equity_issuance","fact_key":"b05897def2af4ebadf551d6e6ca28e3da22f347e","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-02-06T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"stated value of $1,000 per share","effective_date":null,"item_codes_triggered":["3.02","3.03"],"purchaser":"certain accredited investors","security_type":"preferred_stock","shares_text":"1,616.33 shares newly-designated Series C-1 Convertible Preferred Stock"},"claim":"Catheter Precision, Inc. issued 1,616.33 shares newly-designated Series C-1 Convertible Preferred Stock of preferred stock to certain accredited investors for stated value of $1,000 per share.","evidence_excerpt":"of $1.43 (the “Common Shares”) and (ii) 1,616.33 shares newly-designated Series C-1 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, initially convertible into up to 1,130,301shares of Common Stock, at an initial conversion price of $1.43 per share (the “Series C-1 Preferred Stock” and, together with","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-003387","anchor_url":"https://secwatch.observer/filing/0001437749-26-003387#claim-b05897def2af4ebadf551d6e6ca28e3da22f347e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926003387/0001437749-26-003387-index.htm"},{"fact_type":"equity_issuance","fact_key":"144d99fe8e54d2fd0a9429769ae047ecc9ae2562","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-02-06T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$1.43 per share","effective_date":null,"item_codes_triggered":["3.02"],"purchaser":"certain accredited investors","security_type":"common_stock","shares_text":"392,608 shares"},"claim":"Catheter Precision, Inc. issued 392,608 shares of common stock to certain accredited investors for $1.43 per share.","evidence_excerpt":"Placement Financing”) of an aggregate of (i) 392,608 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a per share purchase price of $1.43 (the “Common Shares”) and (ii) 1,616.33 shares newly-designated Series C-1 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-003387","anchor_url":"https://secwatch.observer/filing/0001437749-26-003387#claim-144d99fe8e54d2fd0a9429769ae047ecc9ae2562","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926003387/0001437749-26-003387-index.htm"},{"fact_type":"governance_change","fact_key":"0b90f1fa50d023187184474237c92142ffdedd22","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-02-06T23:59:59+00:00","payload":{"change_type":"fiscal_year_change","effective_date":null,"item_codes_triggered":["5.03"],"summary_text":"Filing of Certificate of Designations for Series C-1 Preferred Stock, referenced as a charter amendment under Item 5.03"},"claim":"Catheter Precision, Inc.: Filing of Certificate of Designations for Series C-1 Preferred Stock, referenced as a charter amendment under Item 5.03.","evidence_excerpt":"Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.","confidence":0.4,"filing_url":"https://secwatch.observer/filing/0001437749-26-003387","anchor_url":"https://secwatch.observer/filing/0001437749-26-003387#claim-0b90f1fa50d023187184474237c92142ffdedd22","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926003387/0001437749-26-003387-index.htm"},{"fact_type":"material_agreement","fact_key":"ea147f2315cb3dc16921b9e4047c0ba1fa7638f5","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2026-02-06T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Financing Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain accredited investors","effective_date":"2026-02-06","item_codes_triggered":["1.01"],"value_text":"$2,177,759.00"},"claim":"Catheter Precision, Inc. entered into Financing Purchase Agreement with certain accredited investors valued at $2,177,759.00 (effective 2026-02-06).","evidence_excerpt":"On February 6, 2026, Catheter Precision, Inc. (the “Company”) entered into a securities purchase agreement (the “Financing Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement Financing”) of an aggregate of (i) 392,608 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a per share purchase price of $1.43 (the “Common Shares”) and (ii) 1,616.33 shares newly-designated Series C-1 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, initially convertible into up to 1,130,301shares of Common Stock, at an initial conversion price of $1.43 per share (the “Series C-1 Preferred Stock” and, together with the Common Shares, the “Initial Securities”), for an aggregate purchase price of $2,177,759.00 with respect to the Initial Securities","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-003387","anchor_url":"https://secwatch.observer/filing/0001437749-26-003387#claim-ea147f2315cb3dc16921b9e4047c0ba1fa7638f5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774926003387/0001437749-26-003387-index.htm"},{"fact_type":"material_agreement","fact_key":"11b09c8f99b1ca89c28bf4826728e4f14553a30a","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2025-11-21T23:59:59+00:00","payload":{"action":"termination","agreement_name":"At-Market-Offering Agreement","agreement_type":"atm_program","counterparty":"Ladenburg Thalmann & Co. Inc.","effective_date":"2025-11-17","item_codes_triggered":["1.02"],"value_text":null},"claim":"Catheter Precision, Inc. terminated At-Market-Offering Agreement with Ladenburg Thalmann & Co. Inc. (effective 2025-11-17).","evidence_excerpt":"On November 17, 2025, Catheter Precision, Inc. (the “Company”) delivered notice to terminate its At-Market-Offering Agreement (the “ATM Agreement”), dated as of May 19, 2025, with Ladenburg Thalmann & Co. Inc. (the “Agent”) providing for the Company’s “at‐the‐market” equity offering program (the “ATM Program”), to be effective as of November 24, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-036000","anchor_url":"https://secwatch.observer/filing/0001437749-25-036000#claim-11b09c8f99b1ca89c28bf4826728e4f14553a30a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925036000/0001437749-25-036000-index.htm"},{"fact_type":"governance_change","fact_key":"4c63451868940eaa3e30c01d6d31e533e673ba89","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2025-08-15T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-08-15","item_codes_triggered":["5.03"],"summary_text":"Filed certificate of amendment to effect a 1-for-19 reverse stock split of common stock."},"claim":"Catheter Precision, Inc.: Filed certificate of amendment to effect a 1-for-19 reverse stock split of common stock (effective 2025-08-15).","evidence_excerpt":"On August 13, 2025, the Company filed a certificate of amendment to the Company’s restated certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the Reverse Stock Split (the “Charter Amendment”). The Charter Amendment became effective at 12:01 a.m. Eastern Time on August 15, 2025","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-027153","anchor_url":"https://secwatch.observer/filing/0001437749-25-027153#claim-4c63451868940eaa3e30c01d6d31e533e673ba89","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925027153/0001437749-25-027153-index.htm"},{"fact_type":"executive_change","fact_key":"376c7a2e81","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"fill","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-02","interim":true,"role":"Chief Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"David Jenkins was appointed as Chief Commercial Officer at Catheter Precision, Inc..","evidence_excerpt":"Mr. David Jenkins, the Company’s Executive Chairman of the Board and Chief Executive Officer, will fill the role of Chief Commercial Officer until a replacement is engaged.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-25-019731","anchor_url":"https://secwatch.observer/filing/0001437749-25-019731#claim-376c7a2e81","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925019731/0001437749-25-019731-index.htm"},{"fact_type":"executive_change","fact_key":"dddbef6691","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"discontinued","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2025-06-02","interim":false,"role":"Chief Commercial Officer","role_category":"other_named_officer","successor_name":"David Jenkins","successor_named":true},"claim":"Marie-Claude Jacques departed as Chief Commercial Officer at Catheter Precision, Inc..","evidence_excerpt":"On June 2, 2025, Catheter Precision, Inc. (the “Company”) discontinued the employment of Marie-Claude Jacques, the Company’s Chief Commercial Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-25-019731","anchor_url":"https://secwatch.observer/filing/0001437749-25-019731#claim-dddbef6691","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925019731/0001437749-25-019731-index.htm"},{"fact_type":"debt_financing","fact_key":"78a999c112258a2af8bb94a13c0566723fd4a431","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2025-05-08T23:59:59+00:00","payload":{"counterparty":"Cardionomic (assignment for the benefit of creditors), LLC","effective_date":"2025-05-05","event":"incurrence","instrument_type":"loan","interest_rate_text":"4% per annum","item_codes_triggered":["2.03"],"maturity_text":"May 5, 2028","principal_text":"$1.5 million"},"claim":"Catheter Precision, Inc. incurred loan of $1.5 million with Cardionomic (assignment for the benefit of creditors), LLC at 4% per annum maturing May 5, 2028.","evidence_excerpt":"the issuance by Cardionomix of a promissory note (the \"Note\") in the amount of $1.5 million, with simple interest accruing at 4% per annum on the principal thereof and no interest or principal payable until the maturity date of the Note, which will be May 5, 2028","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-25-015488","anchor_url":"https://secwatch.observer/filing/0001437749-25-015488#claim-78a999c112258a2af8bb94a13c0566723fd4a431","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925015488/0001437749-25-015488-index.htm"},{"fact_type":"ma_transaction","fact_key":"0cd2be13432a9700f8f6ae9a425a4b3f86c8c947","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2025-05-08T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2025-05-05","consideration_text":"1,000,000 restricted shares of the Company's common stock and a promissory note in the amount of $1.5 million","counterparty":"Cardionomic (assignment for the benefit of creditors), LLC","effective_date":"2025-05-05","item_codes_triggered":["2.01"]},"claim":"Catheter Precision, Inc. completed an acquisition involving Cardionomic (assignment for the benefit of creditors), LLC for 1,000,000 restricted shares of the Company's common stock and a promissory note in the amount of $1.5 million (closed 2025-05-05).","evidence_excerpt":"or warranties as to merchantability, fitness or use from Seller and no representations from or privity with Assignor, in exchange for the issuance by the Company of 1,000,000 restricted shares of the Company's common stock, $0.0001 par value per share (the “Share Consideration”) and the issuance by Cardionomix of a promissory note (the \"Note\") in the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-015488","anchor_url":"https://secwatch.observer/filing/0001437749-25-015488#claim-0cd2be13432a9700f8f6ae9a425a4b3f86c8c947","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925015488/0001437749-25-015488-index.htm"},{"fact_type":"debt_financing","fact_key":"dde266bf4759dee3538e3ec1c67d5308ac556c0f","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2025-04-23T23:59:59+00:00","payload":{"counterparty":"Cardionomic (assignment for the benefit of creditors), LLC","effective_date":"2025-04-22","event":"incurrence","instrument_type":"loan","interest_rate_text":"4% per annum","item_codes_triggered":["2.03"],"maturity_text":"three years following issuance","principal_text":"$1.5 million"},"claim":"Catheter Precision, Inc. incurred loan of $1.5 million with Cardionomic (assignment for the benefit of creditors), LLC at 4% per annum maturing three years following issuance.","evidence_excerpt":"the issuance by Cardionomix of a promissory note (the \"Note\") in the amount of $1.5 million, with simple interest accruing at 4% per annum on the principal thereof and no interest or principal payable until the maturity date of the Note, which will be three years following issuance of the Note.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-25-012731","anchor_url":"https://secwatch.observer/filing/0001437749-25-012731#claim-dde266bf4759dee3538e3ec1c67d5308ac556c0f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925012731/0001437749-25-012731-index.htm"},{"fact_type":"executive_change","fact_key":"e7204c07f7","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2025-01-07T23:59:59+00:00","payload":{"action":"ceased serving","action_category":"role_change","departure_tone":"routine","effective_date":"2025-01-06","interim":false,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":"Philip Anderson","successor_named":true},"claim":"Margrit Thomassen changed role as Interim Chief Financial Officer at Catheter Precision, Inc..","evidence_excerpt":"Ms. Margrit Thomassen, the Company’s previous Interim Chief Financial Officer, ceased serving in that capacity on January 6, 2025 and will continue in the role of Company Controller.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-25-000174","anchor_url":"https://secwatch.observer/filing/0001654954-25-000174#claim-e7204c07f7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495425000174/0001654954-25-000174-index.htm"},{"fact_type":"executive_change","fact_key":"b4b6170e28","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2025-01-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-06","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Philip Anderson was appointed as Chief Financial Officer at Catheter Precision, Inc..","evidence_excerpt":"On January 4, 2025, the Board of Directors of Catheter Precision, Inc. (the “Company”) appointed Philip Anderson as Chief Financial Officer of the Company, effective January 6, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-25-000174","anchor_url":"https://secwatch.observer/filing/0001654954-25-000174#claim-b4b6170e28","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495425000174/0001654954-25-000174-index.htm"},{"fact_type":"executive_change","fact_key":"6ee9fbfb32","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2024-05-21T23:59:59+00:00","payload":{"action":"will not stand for reelection","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-03","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"John P. Francis departed as Director at Catheter Precision, Inc..","evidence_excerpt":"On May 15, 2024, John P. Francis informed the Board of Directors of Catheter Precision, Inc. (the “Company”) that he would not stand for reelection to the Board of Directors of the Company at the Company’s 2024 Annual Meeting of Stockholders scheduled for July 3, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-24-006741","anchor_url":"https://secwatch.observer/filing/0001654954-24-006741#claim-6ee9fbfb32","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424006741/0001654954-24-006741-index.htm"},{"fact_type":"earnings_release","fact_key":"d22331c7225535b0038da9ee6bfe57c010850187","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"($2.7) million","period_text":"the quarter ended March 31, 2024","report_date":"2024-05-06","result_type":"reported_results","revenue_text":"$82 thousand"},"claim":"Catheter Precision, Inc. reported the quarter ended March 31, 2024 results: revenue $82 thousand, net income ($2.7) million.","evidence_excerpt":"were $28 million · Total cash on position at March 31, 2024 was $1.5 million, and $0.5 million at May 6, 2024 · Total revenues for the three months ended March 31, 2024 were $82 thousand · Shareholders’ equity as of March 31, 2024 was $18.5 million · Net loss for the quarter ended March 31, 2024 was ($2.7) million · All revenue as of March 31, 2024 resulted from","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-24-005695","anchor_url":"https://secwatch.observer/filing/0001654954-24-005695#claim-d22331c7225535b0038da9ee6bfe57c010850187","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424005695/0001654954-24-005695-index.htm"},{"fact_type":"earnings_release","fact_key":"f940e94256f3f13a952ed148b6d540cb0bb459d7","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2024-04-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"($70.6) million","period_text":"the quarter and year ended December 31, 2023","report_date":"2024-04-01","result_type":"reported_results","revenue_text":"$442 thousand"},"claim":"Catheter Precision, Inc. reported the quarter and year ended December 31, 2023 results: revenue $442 thousand, net income ($70.6) million.","evidence_excerpt":"Total revenues for the year ended December 31, 2023 were $442 thousand.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-24-004178","anchor_url":"https://secwatch.observer/filing/0001654954-24-004178#claim-f940e94256f3f13a952ed148b6d540cb0bb459d7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424004178/0001654954-24-004178-index.htm"},{"fact_type":"earnings_release","fact_key":"9260b6e6c185f1bf7846fd73e9315b105bfe1b51","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2024-01-11T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss was approximately ($2.5) million for the quarter and ($72.4) million for the year","period_text":"fourth quarter and full year ended December 31, 2023","report_date":"2024-01-10","result_type":"preliminary_results","revenue_text":"$129,000 for the quarter and $442,000 for the year"},"claim":"Catheter Precision, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $129,000 for the quarter and $442,000 for the year, net income net loss was approximately ($2.5) million for the quarter and ($72.4) million for the year.","evidence_excerpt":"results of the fourth quarter and year ended December 31, 2023, include the following: · Total revenues for the quarter and year ended December 31, 2023, were approximately $129,000 and $442,000, respectively. · Total cash on hand as of December 31, 2023, was approximately $3.6 million. · Total assets as of December 31, 2023, subject to adjustment, was $30.7","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-24-000467","anchor_url":"https://secwatch.observer/filing/0001654954-24-000467#claim-9260b6e6c185f1bf7846fd73e9315b105bfe1b51","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424000467/0001654954-24-000467-index.htm"},{"fact_type":"executive_change","fact_key":"d1badb8d31","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2024-01-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-12-28","interim":false,"role":"Director","role_category":"director","successor_name":"John P. Francis","successor_named":true},"claim":"Susanne Meline resigned as Director at Catheter Precision, Inc..","evidence_excerpt":"His appointment fills the vacancy created by the previously reported resignation of Susanne Meline that occurred on December 28, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-24-000194","anchor_url":"https://secwatch.observer/filing/0001654954-24-000194#claim-d1badb8d31","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424000194/0001654954-24-000194-index.htm"},{"fact_type":"executive_change","fact_key":"d9372d5aed","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2024-01-04T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2023-12-31","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Margrit Thomassen","successor_named":true},"claim":"Steve Passey was terminated as Chief Financial Officer at Catheter Precision, Inc..","evidence_excerpt":"Ms. Thomassen replaces Steve Passey, whose employment was terminated on December 28, 2023, effective December 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-24-000194","anchor_url":"https://secwatch.observer/filing/0001654954-24-000194#claim-d9372d5aed","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424000194/0001654954-24-000194-index.htm"},{"fact_type":"executive_change","fact_key":"e8549828f3","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2024-01-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-02","interim":true,"role":"interim Chief Financial Officer and Secretary","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Margrit Thomassen was appointed as interim Chief Financial Officer and Secretary at Catheter Precision, Inc..","evidence_excerpt":"In addition, the Board has named Margrit Thomassen, age 53, to serve as interim Chief Financial Officer and Secretary as of the Effective Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-24-000194","anchor_url":"https://secwatch.observer/filing/0001654954-24-000194#claim-e8549828f3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424000194/0001654954-24-000194-index.htm"},{"fact_type":"executive_change","fact_key":"738dad5418","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2024-01-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-01-02","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"David Jenkins was appointed as Chief Executive Officer at Catheter Precision, Inc..","evidence_excerpt":"Also as of the Effective Date, the Board has named David Jenkins Chief Executive Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-24-000194","anchor_url":"https://secwatch.observer/filing/0001654954-24-000194#claim-738dad5418","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424000194/0001654954-24-000194-index.htm"},{"fact_type":"executive_change","fact_key":"0995c30458","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2024-01-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-02","interim":false,"role":"Class III director","role_category":"director","successor_name":null,"successor_named":false},"claim":"John P. Francis was appointed as Class III director at Catheter Precision, Inc..","evidence_excerpt":"Effective January 2, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of the registrant, Catheter Precision, Inc. (the “Company”), has appointed John P. Francis to serve as a Class III director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-24-000194","anchor_url":"https://secwatch.observer/filing/0001654954-24-000194#claim-0995c30458","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424000194/0001654954-24-000194-index.htm"},{"fact_type":"executive_change","fact_key":"e820a0df9a","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-12-29T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-12-28","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Susanne Meline resigned as Director at Catheter Precision, Inc..","evidence_excerpt":"On December 28, 2023, Susanne Meline tendered her resignation from the Board of Directors of Catheter Precision, Inc. (the “Company”), effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-23-016090","anchor_url":"https://secwatch.observer/filing/0001654954-23-016090#claim-e820a0df9a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423016090/0001654954-23-016090-index.htm"},{"fact_type":"earnings_release","fact_key":"88fc37a732cccba1377f2becb7bed14296f31501","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-12-22T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"three and nine months ended September 30, 2023","report_date":"2023-12-22","result_type":"reported_results","revenue_text":"$314 thousand"},"claim":"Catheter Precision, Inc. reported three and nine months ended September 30, 2023 results: revenue $314 thousand.","evidence_excerpt":"assets at September 30, 2023, were $32.9 million. · Total cash on hand at September 30, 2023 was $5.6 million. · Total revenues for the nine months ended September 30, 2023 were $314 thousand. David Jenkins, acting CEO, commented: “We are pleased to have the Q3 financial filings completed and have a lot of momentum as we move into the fourth quarter. Our sales and","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-015944","anchor_url":"https://secwatch.observer/filing/0001654954-23-015944#claim-88fc37a732cccba1377f2becb7bed14296f31501","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423015944/0001654954-23-015944-index.htm"},{"fact_type":"earnings_release","fact_key":"263d6e62e584f4c5a3188b894ffe32ab2e610d22","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-12-18T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three and six months ended June 30, 2023","report_date":"2023-12-18","result_type":"reported_results","revenue_text":null},"claim":"Catheter Precision, Inc. reported financial results for the three and six months ended June 30, 2023.","evidence_excerpt":"On December 18, 2023, Catheter Precision, Inc. (formerly known as Ra Medical Systems, Inc.) (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.","confidence":0.75,"filing_url":"https://secwatch.observer/filing/0001654954-23-015713","anchor_url":"https://secwatch.observer/filing/0001654954-23-015713#claim-263d6e62e584f4c5a3188b894ffe32ab2e610d22","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423015713/0001654954-23-015713-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"e7d234f09c5c05ced4a2a35ca0ee9ed0d7eae9aa","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-08-25T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nyse_american","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-08-22","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["1007"],"rules_cited_in_text":true},"claim":"Catheter Precision, Inc. received a nyse_american deficiency notice notice regarding late filing (rules 1007).","evidence_excerpt":"August 22, 2023, the Company received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the NYSE American under the timely filing criteria set forth in Section 1007 of the NYSE American Company Guide. The non-compliance results from the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 by the extended filing due date of August 21, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001654954-23-011251","anchor_url":"https://secwatch.observer/filing/0001654954-23-011251#claim-e7d234f09c5c05ced4a2a35ca0ee9ed0d7eae9aa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423011251/0001654954-23-011251-index.htm"},{"fact_type":"earnings_release","fact_key":"4a9d4a4a1b1991075d3316ea43b9aeaf5e45bbc7","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-08-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the six months ended June 30, 2023","report_date":"2023-08-15","result_type":"preliminary_results","revenue_text":"approximately $181,000"},"claim":"Catheter Precision, Inc. reported the six months ended June 30, 2023 results: revenue approximately $181,000.","evidence_excerpt":"On August 15, 2023, Ra Medical Systems, Inc. (the “Company”) filed a Form 12b-25 with the Securities and Exchange Commission that estimated that the Company will recognize revenues of approximately $96,000 for the quarter ended June 30, 2023 and approximately $181,000 for the six months ended June 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-010856","anchor_url":"https://secwatch.observer/filing/0001654954-23-010856#claim-4a9d4a4a1b1991075d3316ea43b9aeaf5e45bbc7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423010856/0001654954-23-010856-index.htm"},{"fact_type":"earnings_release","fact_key":"e23d0f7ea79a98ec1ee43e978c50c43564afa25e","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-08-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended June 30, 2023","report_date":"2023-08-15","result_type":"preliminary_results","revenue_text":"approximately $96,000"},"claim":"Catheter Precision, Inc. reported the quarter ended June 30, 2023 results: revenue approximately $96,000.","evidence_excerpt":"On August 15, 2023, Ra Medical Systems, Inc. (the “Company”) filed a Form 12b-25 with the Securities and Exchange Commission that estimated that the Company will recognize revenues of approximately $96,000 for the quarter ended June 30, 2023 and approximately $181,000 for the six months ended June 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-010856","anchor_url":"https://secwatch.observer/filing/0001654954-23-010856#claim-e23d0f7ea79a98ec1ee43e978c50c43564afa25e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423010856/0001654954-23-010856-index.htm"},{"fact_type":"governance_change","fact_key":"5c2b8d0f8cafc638b1f456c25b3f2ac79bc1976c","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-08-04T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-08-17","item_codes_triggered":["5.03"],"summary_text":"Company filed a certificate of amendment to its certificate of incorporation to change its name from Ra Medical Systems, Inc. to Catheter Precision, Inc., effective August 17, 2023."},"claim":"Catheter Precision, Inc.: Company filed a certificate of amendment to its certificate of incorporation to change its name from Ra Medical Systems, Inc. to Catheter Precision, Inc., effective August 17, 2023 (effective 2023-08-17).","evidence_excerpt":"On August 1, 2023, Ra Medical Systems, Inc., a Delaware corporation (the “Company”), filed a certificate of amendment to its certificate of incorporation with the Secretary of State of Delaware, changing its name to Catheter Precision, Inc.  The name change will be effective on August 17, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-23-010169","anchor_url":"https://secwatch.observer/filing/0001654954-23-010169#claim-5c2b8d0f8cafc638b1f456c25b3f2ac79bc1976c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423010169/0001654954-23-010169-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9d7ed43eb0955865160ee93b5e43488d2774d403","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-07-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-11","outcome":"passed","proposal_text":"Approval of our 2023 Equity Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"2,875","votes_against":"165,641","votes_for":"2,382,822","votes_withheld":null}]},"claim":"Catheter Precision, Inc. shareholders approved Approval of our 2023 Equity Incentive Plan at the 2023-07-11 meeting.","evidence_excerpt":"Our proposed 2023 Equity Incentive Plan was approved based on the following results of voting: Votes For Votes Against Abstentions 2,382,822 165,641 2,875","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-009221","anchor_url":"https://secwatch.observer/filing/0001654954-23-009221#claim-9d7ed43eb0955865160ee93b5e43488d2774d403","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423009221/0001654954-23-009221-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1029244c131762ced66278056c6c1469c89e4e24","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-07-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-11","outcome":"passed","proposal_text":"Election of Two Directors","proposal_type":"director_election","results":[{"broker_non_votes":null,"subject":"Martin Colombatto","votes_abstain":"349","votes_against":"12,322","votes_for":"2,538,669","votes_withheld":null},{"broker_non_votes":null,"subject":"David Jenkins","votes_abstain":"351","votes_against":"11,841","votes_for":"2,539,148","votes_withheld":null}]},"claim":"Catheter Precision, Inc. shareholders approved Election of Two Directors at the 2023-07-11 meeting.","evidence_excerpt":"Martin Colombatto was elected at the Annual Meeting as a Class I director to serve a two-year term, and David Jenkins was elected as a Class II director to serve a three-year term, or until their successors are duly elected and qualified, based on the following results of voting: Votes For Votes Against Abstentions Martin Colombatto 2,538,669 12,322 349 David Jenkins 2,539,148 11,841 351","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-009221","anchor_url":"https://secwatch.observer/filing/0001654954-23-009221#claim-1029244c131762ced66278056c6c1469c89e4e24","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423009221/0001654954-23-009221-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7bc01b885225fef51f3536148d6f3b3fdb3b89c3","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-07-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-11","outcome":"failed","proposal_text":"Approval of a Proposal to Amend our Certificate of Incorporation to Declassify our Board of Directors","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"112,771","votes_against":"11,804","votes_for":"2,426,765","votes_withheld":null}]},"claim":"Catheter Precision, Inc. shareholders rejected Approval of a Proposal to Amend our Certificate of Incorporation to Declassify our Board of Directors at the 2023-07-11 meeting.","evidence_excerpt":"The proposal to amend our certificate of incorporation to declassify our Board of Directors was not approved based on the following results of voting: Votes For Votes Against Abstentions 2,426,765 11,804 112,771","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-009221","anchor_url":"https://secwatch.observer/filing/0001654954-23-009221#claim-7bc01b885225fef51f3536148d6f3b3fdb3b89c3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423009221/0001654954-23-009221-index.htm"},{"fact_type":"auditor_change","fact_key":"35f81eb3ddedff2707ca2e4b6eac4252625cac14","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-06-26T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Haskell & White LLP","disagreement_text":null,"effective_date":"2023-06-21","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"WithumSmith+Brown, PC"},"claim":"Catheter Precision, Inc. dismissed Haskell & White LLP as its auditor.","evidence_excerpt":"On the same date, the Committee approved the dismissal of Haskell as the Company’s independent registered accounting firm","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-008409","anchor_url":"https://secwatch.observer/filing/0001654954-23-008409#claim-35f81eb3ddedff2707ca2e4b6eac4252625cac14","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423008409/0001654954-23-008409-index.htm"},{"fact_type":"auditor_change","fact_key":"865110e314e792ba981c0cae17562ad5581358ab","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-06-26T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"WithumSmith+Brown, PC","disagreement_text":null,"effective_date":"2023-06-21","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Catheter Precision, Inc. engaged WithumSmith+Brown, PC as its auditor.","evidence_excerpt":"on June 21, 2023, the Committee approved the appointment of Withum as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-008409","anchor_url":"https://secwatch.observer/filing/0001654954-23-008409#claim-865110e314e792ba981c0cae17562ad5581358ab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423008409/0001654954-23-008409-index.htm"},{"fact_type":"earnings_release","fact_key":"47f438ee83ea2499b131a0f52e533847904b1eab","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-06-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss was $66.4 million","period_text":"the three months ended March 31, 2023","report_date":"2023-06-02","result_type":"reported_results","revenue_text":"$85 thousand"},"claim":"Catheter Precision, Inc. reported the three months ended March 31, 2023 results: revenue $85 thousand, net income net loss was $66.4 million.","evidence_excerpt":"Passey. · Announced the resignation of its CEO, and appointment of its new Interim CEO, David Jenkins, as of April 28, 2023. · Revenues for the quarter ended March 31, 2023 were $85 thousand, net loss was $66.4 million and cash used by operations was $12.1 million, which includes a $5.0 million cash payment associated with a legacy settlement. Accounting for the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-007595","anchor_url":"https://secwatch.observer/filing/0001654954-23-007595#claim-47f438ee83ea2499b131a0f52e533847904b1eab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423007595/0001654954-23-007595-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"442936111c027eabd6255436ff2f9d9c2f4b25bd","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-05-30T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nyse_american","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-05-23","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["1007"],"rules_cited_in_text":true},"claim":"Catheter Precision, Inc. received a nyse_american deficiency notice notice regarding late filing (rules 1007).","evidence_excerpt":"May 23, 2023, the Company received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the NYSE American under the timely filing criteria set forth in Section 1007 of the NYSE American Company Guide. The non-compliance results from the Company’s previously disclosed failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 by the extended filing due date of May 22, 2023.  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-007353","anchor_url":"https://secwatch.observer/filing/0001654954-23-007353#claim-442936111c027eabd6255436ff2f9d9c2f4b25bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423007353/0001654954-23-007353-index.htm"},{"fact_type":"earnings_release","fact_key":"606090ca7e9e2bc3ff2ee1477b309ec6baf922c1","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-05-22T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2023","report_date":"2023-05-22","result_type":"preliminary_results","revenue_text":"approximately $85,000"},"claim":"Catheter Precision, Inc. reported the quarter ended March 31, 2023 results: revenue approximately $85,000.","evidence_excerpt":"The Company continues to project revenues for the quarter ended March 31, 2023 of approximately $85,000, and also projects that all or substantially all of its goodwill will be written off as a result of the finalization of the purchase price allocation in connection with the Company’s merger with Catheter Precision, Inc.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-007042","anchor_url":"https://secwatch.observer/filing/0001654954-23-007042#claim-606090ca7e9e2bc3ff2ee1477b309ec6baf922c1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423007042/0001654954-23-007042-index.htm"},{"fact_type":"earnings_release","fact_key":"382837335a5bfdb463a4b2573f7eb18c72dcc66f","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-05-16T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter ended March 31, 2022","report_date":"2023-05-16","result_type":"reported_results","revenue_text":"$9,000"},"claim":"Catheter Precision, Inc. reported quarter ended March 31, 2022 results: revenue $9,000.","evidence_excerpt":"revenues of $9,000 were reported in the quarter ended March 31, 2022","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-006726","anchor_url":"https://secwatch.observer/filing/0001654954-23-006726#claim-382837335a5bfdb463a4b2573f7eb18c72dcc66f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423006726/0001654954-23-006726-index.htm"},{"fact_type":"earnings_release","fact_key":"236ccea8aaa0c3560e3b6a103055c04f6ebd344a","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-05-16T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter ended March 31, 2023","report_date":"2023-05-16","result_type":"preliminary_results","revenue_text":"$85,000"},"claim":"Catheter Precision, Inc. reported quarter ended March 31, 2023 results: revenue $85,000.","evidence_excerpt":"The registrant is able to preliminarily project revenues of approximately $85,000 for the quarter ended March 31, 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-23-006726","anchor_url":"https://secwatch.observer/filing/0001654954-23-006726#claim-236ccea8aaa0c3560e3b6a103055c04f6ebd344a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423006726/0001654954-23-006726-index.htm"},{"fact_type":"executive_change","fact_key":"46fc00b5d3","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-04-19T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-04-28","interim":true,"role":"interim Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"David Jenkins was appointed as interim Chief Executive Officer at Catheter Precision, Inc..","evidence_excerpt":"Until a new Chief Executive Officer is identified, David Jenkins, Executive Chairman of the Board, will serve as interim Chief Executive Officer and as the Company’s principal executive officer, effective April 28, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-23-004903","anchor_url":"https://secwatch.observer/filing/0001654954-23-004903#claim-46fc00b5d3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423004903/0001654954-23-004903-index.htm"},{"fact_type":"executive_change","fact_key":"9dcee2e55b","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-04-19T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-04-28","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"David Jenkins","successor_named":true},"claim":"Will McGuire resigned as Chief Executive Officer at Catheter Precision, Inc..","evidence_excerpt":"On April 17, 2023, Ra Medical Systems, Inc. (the “Company”) received the resignation of Will McGuire from his positions as Chief Executive Officer and Secretary, and as a member of the Board of Directors, effective April 28, 2023, for personal reasons.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-23-004903","anchor_url":"https://secwatch.observer/filing/0001654954-23-004903#claim-9dcee2e55b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423004903/0001654954-23-004903-index.htm"},{"fact_type":"executive_change","fact_key":"647004a7ec","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-03-30T23:59:59+00:00","payload":{"action":"replaced","action_category":"departure","departure_tone":"routine","effective_date":"2023-04-01","interim":false,"role":"Acting Chief Financial Officer","role_category":"cfo","successor_name":"Steven Passey","successor_named":true},"claim":"Brian Conn departed as Acting Chief Financial Officer at Catheter Precision, Inc..","evidence_excerpt":"Ra Medical Systems, Inc. (the “Company”) today announced the appointment of Steven Passey as Chief Financial Officer effective April 1, 2023, replacing Brian Conn, who has been serving as Acting Chief Financial Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-23-003933","anchor_url":"https://secwatch.observer/filing/0001654954-23-003933#claim-647004a7ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423003933/0001654954-23-003933-index.htm"},{"fact_type":"executive_change","fact_key":"fa60bcf4b8","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-03-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-04-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Steven Passey was appointed as Chief Financial Officer at Catheter Precision, Inc..","evidence_excerpt":"Ra Medical Systems, Inc. (the “Company”) today announced the appointment of Steven Passey as Chief Financial Officer effective April 1, 2023, replacing Brian Conn, who has been serving as Acting Chief Financial Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-23-003933","anchor_url":"https://secwatch.observer/filing/0001654954-23-003933#claim-fa60bcf4b8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423003933/0001654954-23-003933-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6f411ad3f78025245670c7e06495de393b038aa0","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-21","outcome":"passed","proposal_text":"Approval of adjournment of Special Meeting","proposal_type":"other","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"36,696","votes_against":"87,075","votes_for":"1,181,196","votes_withheld":null}]},"claim":"Catheter Precision, Inc. shareholders approved Approval of adjournment of Special Meeting at the 2023-03-21 meeting.","evidence_excerpt":"5. Proposal No. 5: Approval of the Adjournment of the Special Meeting. The approval of the adjournment of the Special Meeting, if necessary, to continue to solicit votes for Proposal Nos. 1, 2, 3 and 4 was approved based on the following results of voting, although no such adjournment was required as a result of Proposal Nos. 1, 2, 3 and 4 being approved: Votes For Votes Against Abstentions Broker Non-Votes 1,181,196 87,075 36,696 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-23-004187","anchor_url":"https://secwatch.observer/filing/0001564590-23-004187#claim-6f411ad3f78025245670c7e06495de393b038aa0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7174b00766ae3716a78f1205064693ec3d2514d6","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-21","outcome":"passed","proposal_text":"Ratification of independent registered public accounting firm Haskell & White LLP","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"27,203","votes_against":"29,547","votes_for":"1,248,217","votes_withheld":null}]},"claim":"Catheter Precision, Inc. shareholders approved Ratification of independent registered public accounting firm Haskell & White LLP at the 2023-03-21 meeting.","evidence_excerpt":"4. Proposal No. 4: Ratification of Auditors. The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 1,248,217 29,547 27,203 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-23-004187","anchor_url":"https://secwatch.observer/filing/0001564590-23-004187#claim-7174b00766ae3716a78f1205064693ec3d2514d6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm"},{"fact_type":"shareholder_vote","fact_key":"39f73ff16ad7d1f7bfc027c2a63de7dd428f2901","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-21","outcome":"passed","proposal_text":"Approval of issuance of common stock upon conversion of Series X Preferred Stock","proposal_type":"other","results":[{"broker_non_votes":"960,122","subject":null,"votes_abstain":"6,088","votes_against":"70,714","votes_for":"268,043","votes_withheld":null}]},"claim":"Catheter Precision, Inc. shareholders approved Approval of issuance of common stock upon conversion of Series X Preferred Stock at the 2023-03-21 meeting.","evidence_excerpt":"3. Proposal No. 3: Approval, in Accordance with NYSE American Company Guide Section 712(b), the Issuance of Shares of Company Common Stock upon Conversion of Outstanding Series X Preferred Stock. In accordance with NYSE American Company Guide Section 712(b), the issuance of the Common Stock upon conversion of the Company’s Series X Convertible Preferred Stock, par value $0.0001 per share, which shares of Series X Convertible Preferred Stock were issued upon the closing of the merger between the Company and Catheter Precision, Inc., was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 268,043 70,714 6,088 960,122","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-23-004187","anchor_url":"https://secwatch.observer/filing/0001564590-23-004187#claim-39f73ff16ad7d1f7bfc027c2a63de7dd428f2901","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm"},{"fact_type":"shareholder_vote","fact_key":"854584aa03cf70ceb89a58d5ac1bbe3f7491734a","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-21","outcome":"passed","proposal_text":"Approval of issuance of more than 19.99% of common stock in connection with sale of Class A and B units and upon exercise of Series F and G warrants and conversion of Series A Preferred","proposal_type":"other","results":[{"broker_non_votes":"960,122","subject":null,"votes_abstain":"6,613","votes_against":"75,678","votes_for":"262,554","votes_withheld":null}]},"claim":"Catheter Precision, Inc. shareholders approved Approval of issuance of more than 19.99% of common stock in connection with sale of Class A and B units and upon exercise of Series F and G warrants and conversion of Series A Preferred at the 2023-03-21 meeting.","evidence_excerpt":"2. Proposal No. 2: Approval of, in Accordance with NYSE American Company Guide Section 713(a), the Issuance of More than 19.99% of the Company’s Outstanding Common Stock. In accordance with NYSE American Company Guide Section 713(a), the issuance of more than 19.99% of our outstanding Common Stock (a) in connection with our sale of Class A units, which contain shares of common stock and Series F and G Common Stock Purchase Warrants, and Class B units, which contain shares of Series A Convertible Preferred Stock and Series F and G Common Stock Purchase Warrants, and (b) upon the exercise of the Series F and G Common Stock Purchase Warrants and the conversion of Series A Convertible Preferred Stock, with the right for such potential exercise or conversion to occur immediately, was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 262,554 75,678 6,613 960,122","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-23-004187","anchor_url":"https://secwatch.observer/filing/0001564590-23-004187#claim-854584aa03cf70ceb89a58d5ac1bbe3f7491734a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4b1a689ae82392e93d7c2a0d0490d201afe6ec26","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-03-22T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-21","outcome":"passed","proposal_text":"Approval of issuance of more than 19.99% of outstanding common stock upon exercise of Series E warrants","proposal_type":"other","results":[{"broker_non_votes":"960,122","subject":null,"votes_abstain":"7,238","votes_against":"77,670","votes_for":"259,937","votes_withheld":null}]},"claim":"Catheter Precision, Inc. shareholders approved Approval of issuance of more than 19.99% of outstanding common stock upon exercise of Series E warrants at the 2023-03-21 meeting.","evidence_excerpt":"1. Proposal No. 1: Approval of, in Accordance with NYSE American Company Guide Section 713(a), the Issuance of More than 19.99% of the Company’s Outstanding Common Stock. In accordance with NYSE American Company Guide Section 713(a), the issuance of more than 19.99% of our outstanding common stock, par value $0.0001 per share upon the exercise of our Series E Common Stock Purchase Warrants, with the right for such potential exercise to occur immediately, was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 259,937 77,670 7,238 960,122","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-23-004187","anchor_url":"https://secwatch.observer/filing/0001564590-23-004187#claim-4b1a689ae82392e93d7c2a0d0490d201afe6ec26","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm"},{"fact_type":"ma_transaction","fact_key":"63775666699a66b49a1016f55d7cb7eee1906196","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-01-19T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-01-09","consideration_text":null,"counterparty":"Catheter Precision, Inc.","effective_date":"2023-01-09","item_codes_triggered":["2.01"]},"claim":"Catheter Precision, Inc. completed an acquisition involving Catheter Precision, Inc. (closed 2023-01-09).","evidence_excerpt":"On January 9, 2023, Ra Medical Systems, Inc., a Delaware corporation (the “Company” or “Ra Medical”), completed its acquisition (the “Merger”) of Catheter Precision, Inc., a privately-held Delaware corporation (“Catheter”), pursuant to an Amended and Restated Agreement and Plan of Merger, as reported in the Company’s Current Report on Form 8-K filed with the SEC on January 13, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-23-000558","anchor_url":"https://secwatch.observer/filing/0001564590-23-000558#claim-63775666699a66b49a1016f55d7cb7eee1906196","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023000558/0001564590-23-000558-index.htm"},{"fact_type":"governance_change","fact_key":"c2420e6f7fe2f22792f8f08045f4b7a696254c03","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-01-13T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-01-09","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Designation for Series X Convertible Preferred Stock establishing rights, preferences, and limitations"},"claim":"Catheter Precision, Inc.: Filed Certificate of Designation for Series X Convertible Preferred Stock establishing rights, preferences, and limitations (effective 2023-01-09).","evidence_excerpt":"On January 9, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series X Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “Series X Certificate of Designation”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-23-000429","anchor_url":"https://secwatch.observer/filing/0001564590-23-000429#claim-c2420e6f7fe2f22792f8f08045f4b7a696254c03","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023000429/0001564590-23-000429-index.htm"},{"fact_type":"ma_transaction","fact_key":"c7f451dbf3d19551a0d6497279af8f4cac56c9f5","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-01-13T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-01-09","consideration_text":null,"counterparty":"Catheter Precision, Inc.","effective_date":"2023-01-09","item_codes_triggered":["2.01"]},"claim":"Catheter Precision, Inc. completed an acquisition involving Catheter Precision, Inc. (closed 2023-01-09).","evidence_excerpt":"On January 9, 2023, Ra Medical Systems, Inc., a Delaware corporation (the “Company” or “Ra Medical”), completed its acquisition of Catheter Precision, Inc., a privately-held Delaware corporation (“Catheter”), pursuant to an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-23-000429","anchor_url":"https://secwatch.observer/filing/0001564590-23-000429#claim-c7f451dbf3d19551a0d6497279af8f4cac56c9f5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023000429/0001564590-23-000429-index.htm"},{"fact_type":"material_agreement","fact_key":"e78ebc0bbddf6760cbe1bc49343203fa09b81ba0","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-01-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Amended and Restated Agreement and Plan of Merger","agreement_type":"merger","counterparty":"Catheter Precision, Inc., Rapid Merger Sub 1, Inc., and Rapid Merger Sub 2, LLC","effective_date":"2023-01-09","item_codes_triggered":["1.01"],"value_text":null},"claim":"Catheter Precision, Inc. entered into Amended and Restated Agreement and Plan of Merger with Catheter Precision, Inc., Rapid Merger Sub 1, Inc., and Rapid Merger Sub 2, LLC (effective 2023-01-09).","evidence_excerpt":"On January 9, 2023, Ra Medical Systems, Inc., a Delaware corporation (the “Company” or “Ra Medical”), completed its acquisition of Catheter Precision, Inc., a privately-held Delaware corporation (“Catheter”), pursuant to an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Catheter, Rapid Merger Sub 1, Inc., a newly-created wholly-owned subsidiary of the Company (“First Merger Sub”), and Rapid Merger Sub 2, LLC, a newly-created wholly owned subsidiary of the Company (“Second Merger Sub” and together with First Merger Sub, the “Merger Subs”), entered into on January 9, 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-23-000429","anchor_url":"https://secwatch.observer/filing/0001564590-23-000429#claim-e78ebc0bbddf6760cbe1bc49343203fa09b81ba0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023000429/0001564590-23-000429-index.htm"},{"fact_type":"executive_change","fact_key":"23b762af57","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-01-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"James Caruso was appointed as Director at Catheter Precision, Inc..","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, as of immediately following the First Effective Time, Richard Mejia, Jr. and Joan Stafslien resigned from the Board of Directors and any committees of the Board of Directors to which they belonged and David Jenkins (Class II) and James Caruso (Class III) were appointed to the Board of Directors, with Mr. Jenkins becoming Executive Chairperson of the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-23-000429","anchor_url":"https://secwatch.observer/filing/0001564590-23-000429#claim-23b762af57","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023000429/0001564590-23-000429-index.htm"},{"fact_type":"executive_change","fact_key":"f8d0930dfd","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-01-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Executive Chairperson of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"David Jenkins was appointed as Executive Chairperson of the Board at Catheter Precision, Inc..","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, as of immediately following the First Effective Time, Richard Mejia, Jr. and Joan Stafslien resigned from the Board of Directors and any committees of the Board of Directors to which they belonged and David Jenkins (Class II) and James Caruso (Class III) were appointed to the Board of Directors, with Mr. Jenkins becoming Executive Chairperson of the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-23-000429","anchor_url":"https://secwatch.observer/filing/0001564590-23-000429#claim-f8d0930dfd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023000429/0001564590-23-000429-index.htm"},{"fact_type":"executive_change","fact_key":"f06118a0c8","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-01-13T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Joan Stafslien resigned as Director at Catheter Precision, Inc..","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, as of immediately following the First Effective Time, Richard Mejia, Jr. and Joan Stafslien resigned from the Board of Directors and any committees of the Board of Directors to which they belonged and David Jenkins (Class II) and James Caruso (Class III) were appointed to the Board of Directors, with Mr. Jenkins becoming Executive Chairperson of the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-23-000429","anchor_url":"https://secwatch.observer/filing/0001564590-23-000429#claim-f06118a0c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023000429/0001564590-23-000429-index.htm"},{"fact_type":"executive_change","fact_key":"45f7405ee1","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2023-01-13T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Richard Mejia, Jr. resigned as Director at Catheter Precision, Inc..","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, as of immediately following the First Effective Time, Richard Mejia, Jr. and Joan Stafslien resigned from the Board of Directors and any committees of the Board of Directors to which they belonged and David Jenkins (Class II) and James Caruso (Class III) were appointed to the Board of Directors, with Mr. Jenkins becoming Executive Chairperson of the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-23-000429","anchor_url":"https://secwatch.observer/filing/0001564590-23-000429#claim-45f7405ee1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459023000429/0001564590-23-000429-index.htm"},{"fact_type":"earnings_release","fact_key":"5d8531e3a385ebb1d1cda541675624585781057a","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2022-11-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the nine months ended September 30, 2022","report_date":"2022-11-14","result_type":"reported_results","revenue_text":null},"claim":"Catheter Precision, Inc. reported financial results for the nine months ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, Ra Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-22-037674","anchor_url":"https://secwatch.observer/filing/0001564590-22-037674#claim-5d8531e3a385ebb1d1cda541675624585781057a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459022037674/0001564590-22-037674-index.htm"},{"fact_type":"earnings_release","fact_key":"ac81d6534b042d3fec31e1116b3dcff8cedbc1c0","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2022-11-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three months ended September 30, 2022","report_date":"2022-11-14","result_type":"reported_results","revenue_text":null},"claim":"Catheter Precision, Inc. reported financial results for the three months ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, Ra Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001564590-22-037674","anchor_url":"https://secwatch.observer/filing/0001564590-22-037674#claim-ac81d6534b042d3fec31e1116b3dcff8cedbc1c0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459022037674/0001564590-22-037674-index.htm"},{"fact_type":"material_agreement","fact_key":"ad602153527773fa5cde7fe7d7341d96a5890fc8","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2022-11-03T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Lease Termination Agreement","agreement_type":"lease","counterparty":"Anaya Holdings LLC","effective_date":"2022-10-28","item_codes_triggered":["1.02"],"value_text":"released right to $36,017.14 security deposit and paid $300,000 termination fee"},"claim":"Catheter Precision, Inc. terminated Lease Termination Agreement with Anaya Holdings LLC valued at released right to $36,017.14 security deposit and paid $300,000 termination fee (effective 2022-10-28).","evidence_excerpt":"Effective as of October 28, 2022, Ra Medical Systems, Inc. (the “Company”) entered into a lease termination agreement with Anaya Holdings LLC (the “Landlord”) (the “Lease Termination Agreement”) dated October 24, 2022, pursuant to which it terminated its lease agreement relating to the premises located at 2070 Las Palmas Drive, Carlsbad, CA 92011 (the “Lease Agreement”).","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001564590-22-036622","anchor_url":"https://secwatch.observer/filing/0001564590-22-036622#claim-ad602153527773fa5cde7fe7d7341d96a5890fc8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459022036622/0001564590-22-036622-index.htm"},{"fact_type":"executive_change","fact_key":"5facb4200a","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2022-07-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-07-14","interim":true,"role":"interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Brian Conn was appointed as interim Chief Financial Officer at Catheter Precision, Inc..","evidence_excerpt":"On July 14, 2022, the board of directors of the Company appointed Brian Conn to act as interim Chief Financial Officer effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-025910","anchor_url":"https://secwatch.observer/filing/0001564590-22-025910#claim-5facb4200a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459022025910/0001564590-22-025910-index.htm"},{"fact_type":"executive_change","fact_key":"0e05875a53","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2022-07-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-07-08","interim":true,"role":"interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Jonathan Will McGuire was appointed as interim Chief Financial Officer at Catheter Precision, Inc..","evidence_excerpt":"On July 8, 2022, the board of directors of the Company appointed Jonathan Will McGuire to act as interim Chief Financial Officer effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-025910","anchor_url":"https://secwatch.observer/filing/0001564590-22-025910#claim-0e05875a53","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459022025910/0001564590-22-025910-index.htm"},{"fact_type":"executive_change","fact_key":"55f3638e44","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2022-07-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-07-08","interim":true,"role":"interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Jonathan Will McGuire was appointed as interim Chief Financial Officer at Catheter Precision, Inc..","evidence_excerpt":"On July 8, 2022, the board of directors of the Company appointed Jonathan Will McGuire to act as interim Chief Financial Officer effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-025521","anchor_url":"https://secwatch.observer/filing/0001564590-22-025521#claim-55f3638e44","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459022025521/0001564590-22-025521-index.htm"},{"fact_type":"executive_change","fact_key":"39ff0650e8","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2022-05-16T23:59:59+00:00","payload":{"action":"resign","action_category":"departure","departure_tone":"routine","effective_date":"2022-05-25","interim":false,"role":"Chief Financial Officer and Secretary","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Andrew Jackson departed as Chief Financial Officer and Secretary at Catheter Precision, Inc..","evidence_excerpt":"On May 10, 2022, Andrew Jackson notified Ra Medical Systems, Inc. (the “Company”) that he will resign as the Company’s Chief Financial Officer and Secretary, effective May 25, 2022.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001564590-22-020412","anchor_url":"https://secwatch.observer/filing/0001564590-22-020412#claim-39ff0650e8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459022020412/0001564590-22-020412-index.htm"},{"fact_type":"executive_change","fact_key":"97ab0df707","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2021-12-23T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2021-12-31","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"William R. Enquist, Jr. resigned as Director at Catheter Precision, Inc..","evidence_excerpt":"On December 17, 2021, William R. Enquist, Jr. notified Ra Medical Systems, Inc. (the “Company”) that, effective December 31, 2021, he is resigning from the Company’s Board of Directors (the “Board”) as well as from the Nominating and Corporate Governance Committee and the Compensation Committee.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-21-061150","anchor_url":"https://secwatch.observer/filing/0001564590-21-061150#claim-97ab0df707","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459021061150/0001564590-21-061150-index.htm"},{"fact_type":"executive_change","fact_key":"7be8cdd902","cik":1716621,"ticker":"VTAK","company_name":"Catheter Precision, Inc.","filed_at":"2021-07-26T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2021-07-30","interim":false,"role":"General Counsel and Secretary","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"Daniel Horwood resigned as General Counsel and Secretary at Catheter Precision, Inc..","evidence_excerpt":"On July 23, 2021, Daniel Horwood notified Ra Medical Systems, Inc. (the “Company”) that he will resign as the Company’s General Counsel and Secretary, effective July 30, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-21-037789","anchor_url":"https://secwatch.observer/filing/0001564590-21-037789#claim-7be8cdd902","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1716621/000156459021037789/0001564590-21-037789-index.htm"}]}